Design of MYB specific inhibitors

Objective

During my ERC starting grant project, my lab has identified small molecule inhibitors that inhibit the proliferation of MYB-dependent leukemia cell lines. In this proof of concept project, we aim to investigate the potential of these compounds to be further developed as anti-cancer agents. We will determine their potential to inhibit the proliferation breast cancer and colon cancer cell lines and possible additional activity against other solid tumors. In addition, we will investigate the IP landscape and possibilities to improve the chemical properties. These pre-clinical data should provide the basis for the further development of these MYB inhibitors as anti-cancer agents.

Fields of science

• medical and health sciences › clinical medicine › oncology › breast cancer
• medical and health sciences › clinical medicine › oncology › colorectal cancer
• medical and health sciences › clinical medicine › oncology › leukemia

Programme(s)

• FP7-IDEAS-ERC - Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)

Topic(s)

• ERC-OA-2011-PoC - European Research Council ERC Proof of Concept

Call for proposal

ERC-2011-PoC
See other projects for this call

Funding Scheme

CSA-SA(POC) - Supporting action (Proof of Concept)

Host institution

VIB VZW

Address

Rijvisschestraat 120
9052 Zwijnaarde - Gent
Belgium

Activity type

Research Organisations

Administrative Contact

Rik Audenaert (Mr.)

Links

EU contribution

€ 139 100

Beneficiaries (1)

VIB VZW

Belgium

EU contribution

€ 139 100

Address

Rijvisschestraat 120
9052 Zwijnaarde - Gent

Activity type

Research Organisations

Administrative Contact

Rik Audenaert (Mr.)

Links